SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics announced it will report topline results from its…

Cytokinetics, Incorporated · PRESS-RELEASE filed May 4, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed May 4, 2026 at 16:00 ET

Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on May 5, 2026, with a conference call to follow. No results were disclosed in this press release.

  • Topline results from Phase 3 ACACIA-HCM trial to be reported May 5, 2026
  • Trial evaluates aficamten in patients with non-obstructive hypertrophic cardiomyopathy
  • Conference call scheduled for 8:00 AM ET on May 5

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access